Please login to the form below

Not currently logged in
Email:
Password:

cancer patients

This page shows the latest cancer patients news and features for those working in and with pharma, biotech and healthcare.

Genomics England partners with Congenica for genome service

Genomics England partners with Congenica for genome service

The initiative, which was rolled out for testing on cancer patients or those with rare and inherited diseases earlier this month, will provide clinical information on 100, 000 patients, a number ... variant interpretation of genome sequences to the NHS,

Latest news

  • Cancer disruptor F Star names next CEO Cancer disruptor F Star names next CEO

    The co-administration of immunotherapies is expected to be the next cornerstone in cancer treatments. ... We anticipate this synergistic benefit will deliver more targeted, potent and safer treatment options for cancer patients.”.

  • A look ahead to key trial readouts at ESMO A look ahead to key trial readouts at ESMO

    Finally, other studies to look out for at ESMO cover the safety of immunotherapy for HIV patients with cancer, whether women and men experience the same side effects from chemotherapy, if ... Twitter is a reliable information source for cancer patients,

  • Roche preps new Kadcyla filings after phase 3 trial win Roche preps new Kadcyla filings after phase 3 trial win

    Neoadjuvant therapy is given with the intention of achieving a cure for patients with early-stage cancer, and Herceptin and follow-up HER2 drug Perjeta (pertuzumab) have been approved for this ... When patients still have some cancer remaining despite

  • RET rivals Loxo and Blueprint face off with early-stage data RET rivals Loxo and Blueprint face off with early-stage data

    with BLU-667 for at least 24 weeks, and 49% across all patients with that type of cancer. ... In papillary tumours, two of four patients had a partial response and all showed evidence of tumour shrinkage.

  • Gilead strikes deal with NHS England on CAR-T Yescarta

    sciences innovation to NHS patients in a way that is also fair to British taxpayers.”. ... Treatments will continue to improve and become more effective over the coming decade and will benefit patients with other types of cancer.”.

More from news
Approximately 0 fully matching, plus 1,012 partially matching documents found.

Latest Intelligence

  • Cancer care – the power of new technologies Cancer care – the power of new technologies

    With the number of cancer patients on the rise, we need to tackle this disparity by collaborating with the NHS and embracing the power of new technologies. ... on the tumour type that they had, with brain cancer patients highlighting a significantly

  • The future of medicine has to be data-driven The future of medicine has to be data-driven

    How combining AI and expert knowledge is supporting clinicians in the age-old battle against cancer. " /. ... By assembling these data sources, we are entering a new era where we will be able to cluster patients’cancer cases in virtual cohorts and

  • Cancer immunotherapy: What's on the horizon? Cancer immunotherapy: What's on the horizon?

    Opdivo after standard treatment of early-stage lung cancer can reduce recurrences and help patients live longer by killing tumour cells remaining after surgery and standard chemotherapy. ... To sum up, because of the ageing and growing population, there

  • Communication is the key to unlocking the potential of immuno-oncology Communication is the key to unlocking the potential of immuno-oncology

    IO is fast becoming a lifeline to thousands of cancer patients, and has reformed our expectations and hopes for what’s possible in treating cancer. ... And for patients, the practicalities of their cancer treatment have changed.

  • 30 Women Leaders in UK Healthcare

    use in lung cancer patients. ... She is focused on scientific rigour and quality, with a passion for getting things done to ultimately deliver life-changing medicines for cancer patients.

More from intelligence
Approximately 0 fully matching, plus 41 partially matching documents found.

Latest appointments

  • BMS appoints CCO, Stephen Davies joins Eisai and more BMS appoints CCO, Stephen Davies joins Eisai and more

    Apeiron expands board. Cancer Immunotherapy company Apeiron has expanded its board, appointing Anderson Gaweco as its chief medical and scientific officer. ... class new treatments for cancer patients and to help transform the company into a world-class

  • Sue Mahony to retire as president of Lilly Oncology Sue Mahony to retire as president of Lilly Oncology

    We make medicines that help patients with cancer live longer and what a privilege it’s been to wake up each morning with that as my life’s work.”.

  • José Baselga joins BMS’ board of directors José Baselga joins BMS’ board of directors

    Dr Baselga is currently the physician in chief at Memorial Sloan Kettering Cancer Center, where he is responsible for the management of patients care, enhancing and expanding programmes in clinical and ... targeted cancer therapies and treating patients.

  • Taiho Oncology names Timothy Whitten as president Taiho Oncology names Timothy Whitten as president

    to focus on patients with cancer through the development of our robust pipeline and product commercialisation.”. ... I look forward to working with my colleagues at Taiho to ensure that patients continue to benefit from our products now and in the

  • BMS’ Dr Mike Burgees joins Turnstone Biologics BMS’ Dr Mike Burgees joins Turnstone Biologics

    He said: “ Turnstone Biologics is uniquely positioned to deliver breakthrough viral-based immunotherapies for patients with cancer. ... I look forward to working closely with Turnstone’s experienced team and founders, who are driven by science and

More from appointments
Approximately 0 fully matching, plus 30 partially matching documents found.

Latest from PMHub

  • Genetic counsellors: the new healthcare influencers?

    patients. In April 2018, Medicare &Medicaid Services  announced patients with advanced cancer will have free access to genetic testing. ... to recommend genetic testing to high-risk breast cancer patients, despite the women asking for tests.

  • Patient Engagement for the Life Sciences

    I think it delivers value for the industry, but also for patients and society at large. ... He’ s a patient expert himself, he’ s a EUPATI scholar, and he’ s built a virtual patient network for patients with cancer.

  • Patient Engagement for the Life Sciences

    I think it delivers value for the industry, but also for patients and society at large. ... He’ s a patient expert himself, he’ s a EUPATI scholar, and he’ s built a virtual patient network for patients with cancer.

  • Successful brands tell stories

    An oncology tale. In 2017 Blue Latitude Health was asked to develop differentiated and convincing global messaging for physicians helping prostate cancer patients. ... The stories stood out and supported broader conversations, which gave a voice to

  • SWITCHED ONcology Patient Experience Focus Group Full Discussion

    SWITCHED ONcology Patient Experience Focus Group Full Discussion. On 22nd February we held our patient experience focus group, which brought together patients, doctors and industry advocates to discuss the changing landscape ... around treatment, access

More from PMHub
Approximately 1 fully matching, plus 21 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Aptus Health

Aptus Health is dedicated to advancing health engagement. The company offers end-to-end digital health engagement solutions spanning all areas of...

Latest intelligence

patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe's leading hub for life sciences innovation...

Infographics